Cue Biopharma (CUE) News Today → The World’s Richest Man Blindsided by AI (From Banyan Hill Publishing) (Ad) Free CUE Stock Alerts $1.55 -0.10 (-6.06%) (As of 04:30 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11 at 12:18 PM | finance.yahoo.comCue Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)May 10, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | globenewswire.comCue Biopharma to Present at the 20th Annual PEGS Boston SummitMay 7, 2024 | finance.yahoo.comCue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceApril 30, 2024 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) Short Interest UpdateCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 4,780,000 shares, a growth of 13.8% from the March 31st total of 4,200,000 shares. Based on an average daily trading volume, of 256,300 shares, the days-to-cover ratio is presently 18.7 days.April 24, 2024 | globenewswire.comCue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 9, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For Cue BiopharmaApril 9, 2024 | marketbeat.comStifel Nicolaus Reiterates "Buy" Rating for Cue Biopharma (NASDAQ:CUE)Stifel Nicolaus reiterated a "buy" rating and set a $8.00 price objective on shares of Cue Biopharma in a research report on Tuesday.April 9, 2024 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 9, 2024 | finance.yahoo.comCue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...April 8, 2024 | markets.businessinsider.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | globenewswire.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, April 08, 2024April 7, 2024 | markets.businessinsider.comCue Biopharma is about to announce earnings — here's what Wall Street expectsApril 3, 2024 | marketbeat.comCue Biopharma (NASDAQ:CUE) Receives Overweight Rating from Piper SandlerPiper Sandler restated an "overweight" rating and set a $8.00 price objective on shares of Cue Biopharma in a research report on Wednesday.April 2, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023April 2, 2024 | finance.yahoo.comCue Biopharma to Host Business Update Call and WebcastApril 2, 2024 | finance.yahoo.comCue Biopharma to Host Business Update Call and WebcastApril 1, 2024 | msn.comCarisma to cut 37% of workforce, stock falls 8%March 18, 2024 | marketbeat.comCue Biopharma (CUE) to Release Quarterly Earnings on TuesdayCue Biopharma (NASDAQ:CUE) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.March 13, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Silence TherapeuticsMarch 13, 2024 | marketbeat.comCue Biopharma (NASDAQ:CUE) Coverage Initiated at Jefferies Financial GroupJefferies Financial Group initiated coverage on Cue Biopharma in a report on Wednesday. They set a "buy" rating and a $6.00 price target on the stock.February 29, 2024 | finance.yahoo.comCue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumFebruary 29, 2024 | globenewswire.comCue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumFebruary 27, 2024 | morningstar.comCue Biopharma Inc Ordinary SharesFebruary 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)February 6, 2024 | finance.yahoo.comCue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 6, 2024 | finance.yahoo.comCue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 1, 2024 | marketbeat.comCue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 6.7% in JanuaryCue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,650,000 shares, an increase of 6.7% from the December 31st total of 3,420,000 shares. Based on an average daily volume of 361,500 shares, the short-interest ratio is currently 10.1 days.January 17, 2024 | finance.yahoo.comCue Biopharma (NASDAQ:CUE) investors are sitting on a loss of 80% if they invested three years agoJanuary 16, 2024 | marketbeat.comShort Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Expands By 5.2%Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, an increase of 5.2% from the December 15th total of 3,250,000 shares. Based on an average daily trading volume, of 362,400 shares, the short-interest ratio is currently 9.4 days.January 3, 2024 | marketbeat.comShort Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Rises By 8.3%Cue Biopharma, Inc. (NASDAQ:CUE - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,250,000 shares, a growth of 8.3% from the November 30th total of 3,000,000 shares. Based on an average trading volume of 341,700 shares, the days-to-cover ratio is presently 9.5 days.December 14, 2023 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q3 2023December 7, 2023 | finance.yahoo.comAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?November 22, 2023 | finance.yahoo.comCue Biopharma to Present at the JMP Securities Hematology and Oncology SummitNovember 12, 2023 | finance.yahoo.comCue Biopharma, Inc. (NASDAQ:CUE) Q3 2023 Earnings Call TranscriptNovember 10, 2023 | msn.comCue Biopharma reports Q3 resultsNovember 10, 2023 | finance.yahoo.comCue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 9, 2023 | finance.yahoo.comCue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsNovember 8, 2023 | morningstar.comCue Biopharma Inc Ordinary Shares CUENovember 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cue Biopharma (CUE) and Mirati Therapeutics (MRTX)November 7, 2023 | finance.yahoo.comCue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in NovemberNovember 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cue Biopharma (CUE), Zoetis (ZTS) and CymaBay Therapeutics (CBAY)November 3, 2023 | finance.yahoo.comCue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023September 28, 2023 | finance.yahoo.comAcadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains?September 27, 2023 | finance.yahoo.comCue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 26, 2023 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered. Click here now to see his shocking evidence. CUE Media Mentions By Week CUE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CUE News Sentiment▼0.920.57▲Average Medical News Sentiment CUE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CUE Articles This Week▼91▲CUE Articles Average Week Get Cue Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Assertio News Allakos News Citius Pharmaceuticals News Genelux News IO Biotech News PMV Pharmaceuticals News BeyondSpring News Adagene News Oramed Pharmaceuticals News Relmada Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CUE) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
